Valeant: Here Come the Buyers?

S&P Global Market Intelligence's Jeffrey Loo explains why he's maintaining his Buy rating on Valeant Pharmaceuticals International ( VRX ) following reports it had rejected a takeover bid earlier this year:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.